1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generic Drug

The Business of Generics: Market Trends & Strategies Explained

  • Currently 4/5 Stars.
  • 1
  • 2
  • 3
  • 4
  • 5
24 votes

Global Generic Drug Industry

The generic drug industry (as a part of the pharmaceutical business) covers the marketing and sale of medication containing the same active ingredients and dosages as brand-name drugs manufactured by the pharmaceutical industry. Drugs can be prescribed under their chemical name without specifying a particular pharmaceutical brand or company. A key benefit of generic drugs is that they usually cost a fraction of the price of brand-name drugs, as much as 80% to 85% less according to the US Food and Drug Administration. For example, Glucotrol, a drug used in the treatment of diabetes, represents a monthly cost to patients of between $42 and $84 for 10 mg tablets; however, the drug’s generic version, Glipizide, costs up to 10 times less at between $4 and $8 per month.

Generic drugs are under the same governance as brand-name drugs and must adhere to the same standards. When brand-name drugs come off patent, the market is opened up to generic versions. Patent protection generally protects a drug’s intellectual property rights for about 20 years, but as the patent is effective from the clinical trial stage, the actual time the drug is on the market can be far less, often between 10 and 14 years. After a patent expires, pharmaceutical companies come under fierce pricing pressure due to competition from their less-expensive generic counterparts.

Generics help reduce government spending on healthcare, accounting in part for a near 5% decrease in US drug spending, reports the FDA. The FDA acts as a governing body for generic drugs to enforce maximum standards of variation with brand-name drugs. However, in an 11-year study, variation in absorption of branded and generic drugs was found to be as little as 3.5%. Such negligible variation could equally exist in a comparison of two branded drugs.

Best-Selling Generic Drugs

Generic drugs took all of the top-10 spots for the most-prescribed drugs in the US last year, as ranked by the IMS Institute for Healthcare Informatics. Only three brand-name drugs ranked in the top 25, highlighting the strong foothold secured by generics.

Possibly further boosting future sales is the looming patent expiration of several of the pharmaceutical world’s star prescription brand-name drugs, for which generics are poised to claim a sizeable market share. Top generic drugs to enter the market this year are expected to be Methylphenidate (an attention deficit hyperactivity disorder drug taking over from Concerta) and Levofloxacin (a copy of antibiotic Levaquin).

Other generics set to take over from brand-name drugs include:

  • Fenofibrate based on the cholesterol drug Tricor
  • Montelukast based on asthma and allergy treatment Singulair
  • Pioglitazone based on the diabetic drug Actos
  • Valsartan based on the high blood pressure medication Diovan

Industry Leaders

BCC Research shows Teva Pharmaceutical Industries to hold just under 20% of the global generic drugs market, followed by Sandoz, with 10% of the market. In joint third place are Watson and Mylan, with 6% each. Together, Teva, Sandoz, Watson, and Mylan hold a combined 40% share of the global market.

Generic Drug Industry Trends

The generic drug market is gaining increasing ground over brand-name pharmaceuticals, with the FDA reporting that generics account for more than 70% of prescription drugs in the US. 

 

Leading Associations

Share

You might be interested in these related markets:

24/7 Customer Support

Talk to Sam

0044 208 068 8943

1-10 of about 300 reports

Global Generic Drug Industry

  • February 2016
    25 pages
  • Generic Drug  

    Pharmaceutical  

    Biosimilar  

  • World  

    India  

    Europe  

View report >

Generic Drug Industry in the US

  • May 2017
    55 pages
  • Generic Drug  

  • United States  

View report >

Generic Drug Industry in Europe

  • June 2017
    9 pages
  • Biosimilar  

  • Europe  

    Portugal  

View report >

Generic Drug Demand Analysis in Japan - Forecast

  • January 2016
    13 pages
  • Generic Drug  

    Pharmacy  

  • Japan  

View report >

The future of the Generic Drug Industry in the UK

  • February 2017
    6 pages
  • Generic Drug  

  • United Kingdom  

View report >

Generic Drug Industry in Canada

  • October 2016
    18 pages
  • Generic Drug  

  • Canada  

View report >

Generic Drug Industry in China - Forecast

  • January 2016
    12 pages
  • Pharmaceutical  

    Generic Drug  

  • China  

    Asia  

View report >

Generic Drug Industry in Australia - Forecast

  • January 2017
    9 pages
  • Generic Drug  

    Biosimilar  

  • Australia  

    OECD  

    Oceania  

View report >

Generic Drug Industry in Australia - Forecast

  • January 2017
    9 pages
  • Generic Drug  

    Biosimilar  

  • Australia  

    OECD  

    Oceania  

View report >

Generic Drug Industry in Australia

  • September 2016
    8 pages
  • Generic Drug  

  • Australia  

View report >

Search in Generic Drug Industry (About 300 reports)
Parent industry: Pharmaceutical
Related industries: Drug Delivery, Drug Discovery and Development, OTC, Pharmacy, Prescription Drug, Therapy

87 reports

Purchase Reports From Reputable Market Research Publishers
(From € 181 - € 3636)

Generic Drugs Markets in China

  • € 3636
  • Industry report
  • May 2017
  • by Asia Market Information & Development Company

China’s demand for Generic Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth ...

Generic Drugs Companies In China

May 2017 € 1636

Generic Drugs Industry Forecasts - China Focus

May 2017 € 1636

Fumarate De Formoterol- Drug Insights, 2017

July 2017 € 909

The 2018-2023 World Outlook For Generic Biosimilars

April 2017 € 905

The 2018-2023 World Outlook For Generic Prescription Dr ...

April 2017 € 905

Brand Name Pharmaceutical Manufacturing In Canada - Ind ...

May 2017 € 750

Fumarate De Formoterol - Api Insights, 2017

July 2017 € 455

2017 U.s. General Accounting Services Sold Through Offi ...

May 2017 € 181

The 2018-2023 World Outlook For Generic Biosimilars

April 2017 € 905

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.